SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Mimedx Group, Inc. – ‘10-K’ for 12/31/12 – ‘R47’

On:  Friday, 3/15/13, at 5:14pm ET   ·   For:  12/31/12   ·   Accession #:  1140361-13-12765   ·   File #:  0-52491

Previous ‘10-K’:  ‘10-K/A’ on 6/21/12 for 12/31/11   ·   Next:  ‘10-K’ on 3/4/14 for 12/31/13   ·   Latest:  ‘10-K’ on 2/28/24 for 12/31/23

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/15/13  Mimedx Group, Inc.                10-K       12/31/12   70:10M                                    Broadridge Fin’l So… Inc

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Mimedx Group Inc 10-K 12-31-2012                    HTML   1.04M 
 2: EX-10.54    Material Contract                                   HTML     39K 
 3: EX-10.55    Material Contract                                   HTML     27K 
 4: EX-10.56    Material Contract                                   HTML     96K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     19K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     27K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     21K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     21K 
47: R1          Document and Entity Information                     HTML     48K 
37: R2          Consolidated Balance Sheets                         HTML    126K 
45: R3          Consolidated Balance Sheets (Parenthetical)         HTML     56K 
49: R4          Consolidated Statements of Operations               HTML     70K 
64: R5          Consolidated Statements of Stockholders' Equity     HTML    130K 
39: R6          Consolidated Statements of Stockholders' Equity     HTML     22K 
                (Parenthetical)                                                  
44: R7          Consolidated Statements of Cash Flows               HTML    150K 
34: R8          Consolidated Statements of Cash Flows               HTML     76K 
                (Parenthetical)                                                  
26: R9          Nature of Business                                  HTML     24K 
66: R10         Significant Accounting Policies                     HTML    124K 
51: R11         Liquidity and Management's Plans                    HTML     22K 
50: R12         Acquisition of Surgical Biologics, LLC              HTML     85K 
55: R13         Inventories                                         HTML     33K 
56: R14         Property and Equipment                              HTML     36K 
54: R15         Intangible Assets and Royalty Agreement             HTML     96K 
57: R16         Accrued Expenses                                    HTML     30K 
46: R17         Long-Term Debt                                      HTML     54K 
48: R18         Common Stock Placements                             HTML     36K 
53: R19         Equity                                              HTML    185K 
70: R20         Income Taxes                                        HTML     58K 
60: R21         Related Party Transactions                          HTML     38K 
41: R22         401k Plan                                           HTML     30K 
52: R23         Commitments                                         HTML     30K 
43: R24         Subsequent Events                                   HTML     24K 
20: R25         Significant Accounting Policies (Policies)          HTML    222K 
61: R26         Significant Accounting Policies (Tables)            HTML     65K 
67: R27         Acquisition of Surgical Biologics, LLC (Tables)     HTML     72K 
30: R28         Inventories (Tables)                                HTML     30K 
29: R29         Property and Equipment (Tables)                     HTML     33K 
32: R30         Intangible Assets and Royalty Agreement (Tables)    HTML     96K 
33: R31         Accrued Expenses (Tables)                           HTML     27K 
35: R32         Long-Term Debt (Tables)                             HTML     47K 
19: R33         Equity (Tables)                                     HTML    182K 
58: R34         Income Taxes (Tables)                               HTML     50K 
40: R35         Related Party Transactions (Tables)                 HTML     33K 
42: R36         Commitments (Tables)                                HTML     25K 
23: R37         Nature of Business (Details)                        HTML     21K 
69: R38         Significant Accounting Policies (Details)           HTML    157K 
16: R39         Liquidity and Management's Plans (Details)          HTML     31K 
36: R40         Acquisition of Surgical Biologics, LLC (Details)    HTML    177K 
63: R41         Inventories (Details)                               HTML     38K 
22: R42         Property and Equipment (Details)                    HTML     34K 
28: R43         Intangible Assets and Royalty Agreement (Details)   HTML    122K 
31: R44         Accrued Expenses (Details)                          HTML     31K 
38: R45         Long-Term Debt (Details)                            HTML    116K 
18: R46         Common Stock Placements (Details)                   HTML     70K 
25: R47         Equity (Details)                                    HTML    285K 
17: R48         Income Taxes (Details)                              HTML     95K 
62: R49         Related Party Transactions (Details)                HTML     31K 
21: R50         401k Plan (Details)                                 HTML     32K 
59: R51         Commitments (Details)                               HTML     28K 
24: R52         Subsequent Events (Details)                         HTML     37K 
68: XML         IDEA XML File -- Filing Summary                      XML     94K 
27: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.52M 
10: EX-101.INS  XBRL Instance -- mdxg-20121231                       XML   2.21M 
12: EX-101.CAL  XBRL Calculations -- mdxg-20121231_cal               XML    193K 
13: EX-101.DEF  XBRL Definitions -- mdxg-20121231_def                XML    640K 
14: EX-101.LAB  XBRL Labels -- mdxg-20121231_lab                     XML   2.22M 
15: EX-101.PRE  XBRL Presentations -- mdxg-20121231_pre              XML   1.17M 
11: EX-101.SCH  XBRL Schema -- mdxg-20121231                         XSD    203K 
65: ZIP         XBRL Zipped Folder -- 0001140361-13-012765-xbrl      Zip    225K

‘R47’   —   Equity (Details)

This is an IDEA Financial Report.  [ Alternative Formats ]

 
v2.4.0.6
Equity (Details) (USD $)
 12 Months Ended 12 Months Ended 12 Months Ended
Plans
Warrants [Member]
Warrants [Member]
Contingent Warrants [Member]
Contingent Warrants [Member]
Warrants Issued in Connection with Private Placement [Member]
Warrants [Member]
Warrants Issued in Connection with Private Placement [Member]
Warrants [Member]
Warrants Issued in Connection with Private Placement [Member]
Contingent Warrants [Member]
Warrants Issued in Connection with Private Placement [Member]
Contingent Warrants [Member]
Warrants Issued in Connection with Convertible Promissory Notes [Member]
Warrants [Member]
Warrants Issued in Connection with Convertible Promissory Notes [Member]
Contingent Warrants [Member]
Warrants Issued In Connection With Line of Credit with Related Party [Member]
Warrants [Member]
Warrants Issued In Connection With Line of Credit with Related Party [Member]
Warrants [Member]
Warrants Issued In Connection With Line of Credit with Related Party [Member]
Contingent Warrants [Member]
Warrants Issued In Connection With Line of Credit with Related Party [Member]
Contingent Warrants [Member]
Warrants Issued in Connection with Senior Secured Promissory Notes. [Member]
Warrants [Member]
Warrants Issued in Connection with Senior Secured Promissory Notes. [Member]
Contingent Warrants [Member]
Callable warrants [Member]
Warrants [Member]
Callable warrants [Member]
Contingent Warrants [Member]
Warrants expired [Member]
Warrants [Member]
Warrants expired [Member]
Contingent Warrants [Member]
Contingent warrants related to convertible note [Member]
Warrants [Member]
Contingent warrants related to convertible note [Member]
Contingent Warrants [Member]
Other [Member]
Warrants [Member]
Other [Member]
Contingent Warrants [Member]
Warrants Redeemed for Cashless Exercises [Member]
Warrants [Member]
Warrants Redeemed for Cashless Exercises [Member]
Contingent Warrants [Member]
Repurchase of callable warrants [Member]
Warrants [Member]
Repurchase of callable warrants [Member]
Contingent Warrants [Member]
Placement Agent [Member]
Warrants [Member]
Placement Agent [Member]
Contingent Warrants [Member]
$0.50 [Member]
$0.65-$1.00 [Member]
$1.04-$1.80 [Member]
$2.40 [Member]
$0.50-$0.76 [Member]
$0.87-$1.35 [Member]
$1.40-$2.18 [Member]
$2.29-$3.47 [Member]
$3.49-$3.85 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                                                                                  
Number of share-based compensation plans 3                                                                                
Outstanding assumed options (in shares) 375,000                                                                                
Shares authorized (in shares) 16,500,000 12,500,000                                                                              
Increase of shares (in shares) 4,000,000                                                                                
Number of shares [Roll forward]                                                                                  
Outstanding, beginning of period (in shares) 10,333,583 8,257,650                                                                              
Granted (in shares) 5,307,500 3,918,500                                                                              
Exercised (in shares) (843,862) (490,000)                                                                              
Unvested options forfeited (in shares) (387,171) (217,252)                                                                              
Vested options expired (in shares) (795,915) (1,135,315)                                                                              
Outstanding, end of period (in shares) 13,614,135 10,333,583                                                                              
Vested or expected to vest at end of period (in shares) 13,367,278 10,283,583                                                                              
Weighted-Average Exercise Price [Roll forward]                                                                                  
Outstanding, weighted average exercise price, beginning of period (in dollars per share) $ 1.17 $ 1.20                                                                              
Granted, weighted average exercise price (in dollars per share) $ 1.90 $ 1.17                                                                              
Exercised, weighted average exercise price (in dollars per share) $ 1.25 $ 0.60                                                                              
Unvested options forfeited weighted-average exercise price (in dollars per share) $ 1.17 $ 1.10                                                                              
Vested options expired weighted-average exercise price (in dollars per share) $ 1.55 $ 1.70                                                                              
Outstanding, weighted average exercise price, end of period (in dollars per share) $ 1.42 $ 1.17                                                                              
Vested or expected to vest at end of period weighted average exercise price (in dollars per share) $ 1.41 $ 1.17                                                                              
Stock options, additional disclosures [Abstract]                                                                                  
Outstanding, weighted average remaining contractual term 8 years 7 years 1 month 6 days                                                                              
Vested and expected to vest, weighted average remaining contractual term 7 years 10 months 24 days 5 years 8 months 12 days                                                                              
Outstanding, aggregate intrinsic value $ 32,924,881 $ 1,457,218                                                                              
Vested and expected to vest, aggregate intrinsic value 32,490,930 1,395,223                                                                              
Exercised options, intrinsic value 718,978 258,000                                                                              
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]                                                                                  
Exercise Price Range, lower range limit (in dollars per share)                                                                   $ 0.65 $ 1.04   $ 0.50 $ 0.87 $ 1.40 $ 2.29 $ 3.49
Exercise Price Range, upper range limit (in dollars per share)                                                                 $ 0.50 $ 1.00 $ 1.80 $ 2.40 $ 0.76 $ 1.35 $ 2.18 $ 3.47 $ 3.85
Number of outstanding options (in shares) 13,614,135 10,333,583                                                             587,250 2,967,500 6,228,833 550,000 2,372,500 7,048,668 1,958,467 2,177,000 57,500
Outstanding Options, weighted average remaining contractual term 8 years 7 years 1 month 6 days                                                             2 years 10 months 24 days 5 years 8 months 12 days 8 years 9 months 18 days 8 months 12 days 5 years 3 months 18 days 8 years 7 months 6 days 6 years 9 months 18 days 9 years 8 months 12 days 10 years
Outstanding Options, weighted average exercise price (in dollars per share) $ 1.42 $ 1.17                                                             $ 0.50 $ 0.79 $ 1.30 $ 2.40 $ 0.66 $ 1.15 $ 1.68 $ 0 $ 0
Number of exercisable options (in shares) 5,236,597 6,000,497                                                             513,268 2,730,224 2,207,005 550,000 2,372,500 1,674,638 1,189,459 0 0
Exercisable Options, weighted average exercise price (in dollars per share) $ 1.05 $ 1.16                                                             $ 0.50 $ 0.79 $ 1.45 $ 2.40 $ 0.66 $ 1.15 $ 1.68 $ 0 $ 0
Total unrecognized compensation expense $ 6,151,000                                                                                
Unvested Stock Options [Rollforward]                                                                                  
Unvested at beginning of year (in shares) 4,333,086 2,679,787                                                                              
Granted (in shares) 5,307,500 3,918,500                                                                              
Called/expired (in shares) (387,171) (1,352,567)                                                                              
Vested (in shares) (875,877) (912,634)                                                                              
Unvested at end of year (in shares) 8,377,538 4,333,086                                                                              
Unvested Stock Option Weighted Average Grant Date Fair Value [Roll Forward]                                                                                  
Unvested at beginning of year (in dollars per share) $ 0.72 $ 0.87                                                                              
Granted (in dollars per share) $ 1.90 $ 0.63                                                                              
Cancelled/expired (in dollars per share) $ 1.17 $ 0.59                                                                              
Vested (in dollars per share) $ 1.05 $ 0.81                                                                              
Unvested at end of year (in dollars per share) $ 0.96 $ 0.72                                                                              
Fair value options valuation assumptions [Abstract]                                                                                  
Expected volatility, minimum (in hundredths) 45.70% 57.30%                                                                              
Expected volatility, maximum (in hundredths) 64.30% 58.10%                                                                              
Expected life (in years) 6 years 6 years                                                                              
Expected dividend yield (in hundredths) 0.00% 0.00%                                                                              
Risk-free interest rate, minimum (in hundredths) 0.62% 0.86%                                                                              
Risk-free interest rate, maximum (in hundredths) 0.177% 2.24%                                                                              
Weighted-average grant date fair value for options granted during the period (in dollars per share) $ 1.07 $ 0.63                                                                              
Class of Warrant or Right [Line Items]                                                                                  
Warrants, term 5 years                                                                                
Warrants, Number of Warrants [Roll Forward]                                                                                  
Warrants outstanding, beginning of period (in shares)     9,388,817 6,003,924 5,245,484 1,252,990                                                                      
Contingent warrants issued (in shares)             1,672,743 1,889,161 (1,672,743) 1,889,162 203,332 203,332 325,000 0 (325,000) 650,000 1,250,000 1,250,000                         42,400 0                  
Warrants voided (in shares)     0   (3,247,741)                                                                        
Warrants exercised (in shares)             (1,608,802)   0       (325,000)   0       (3,288,733) 0     (1,249,750) 0 (1,703,568) 0 (14,789) 0 (56,750) 0                      
Expired warrants (in shares)                                         (10,000) 0                                      
Warrants outstanding, end of period (in shares)     3,129,168 6,003,924 0 1,252,990                                                                      
Warrants, Weighted-Average Exercise Price per Warrant [Roll Forward]                                                                                  
Warrants outstanding, beginning of period (in dollars per share)     $ 1.00 $ 1.21 $ 0.01 $ 0.01                                                                      
Warrants issued (in dollars per share)     $ 0   $ 0.01   $ 0.01 $ 1.50 $ 0.01 $ 0.01 $ 1.50 $ 0.01 $ 0.01 $ 0 $ 0.01 $ 0.01 $ 0.01 $ 0.01                         $ 1.09 $ 0                  
Warrants exercised (in dollars per share)             $ 0.01   $ 0       $ 0.01   $ 0       $ 1.50 $ 0     $ 0.01 $ 0 $ 0.63 $ 0 $ 0.53 $ 0 $ 1.50 $ 0                      
Warrants Expired Weighted Average Exercise Price (in dollars per share)                                         $ 1.00 $ 0                                      
Warrants outstanding, end of period (in dollars per share)     $ 1.04 $ 1.21 $ 0 $ 0.01                                                                      

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/15/13
For Period end:12/31/12
12/31/1110-K,  10-K/A
12/31/1010-K,  10-K/A,  4
9/15/094
 List all Filings 
↑Top
Filing Submission 0001140361-13-012765   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., Apr. 30, 12:17:43.1am ET